227 related articles for article (PubMed ID: 23103871)
21. Domain one of the high affinity IgE receptor, FcepsilonRI, regulates binding to IgE through its interface with domain two.
Rigby LJ; Epa VC; Mackay GA; Hulett MD; Sutton BJ; Gould HJ; Hogarth PM
J Biol Chem; 2000 Mar; 275(13):9664-72. PubMed ID: 10734118
[TBL] [Abstract][Full Text] [Related]
22. Conformational plasticity at the IgE-binding site of the B-cell receptor CD23.
Dhaliwal B; Pang MO; Yuan D; Yahya N; Fabiane SM; McDonnell JM; Gould HJ; Beavil AJ; Sutton BJ
Mol Immunol; 2013 Dec; 56(4):693-7. PubMed ID: 23933509
[TBL] [Abstract][Full Text] [Related]
23. Identification of contact residues in the IgE binding site of human FcepsilonRIalpha.
Cook JP; Henry AJ; McDonnell JM; Owens RJ; Sutton BJ; Gould HJ
Biochemistry; 1997 Dec; 36(50):15579-88. PubMed ID: 9398286
[TBL] [Abstract][Full Text] [Related]
24. The structure of the IgE Cepsilon2 domain and its role in stabilizing the complex with its high-affinity receptor FcepsilonRIalpha.
McDonnell JM; Calvert R; Beavil RL; Beavil AJ; Henry AJ; Sutton BJ; Gould HJ; Cowburn D
Nat Struct Biol; 2001 May; 8(5):437-41. PubMed ID: 11323720
[TBL] [Abstract][Full Text] [Related]
25. Disulfide linkage controls the affinity and stoichiometry of IgE Fcepsilon3-4 binding to FcepsilonRI.
Hunt J; Beavil RL; Calvert RA; Gould HJ; Sutton BJ; Beavil AJ
J Biol Chem; 2005 Apr; 280(17):16808-14. PubMed ID: 15743766
[TBL] [Abstract][Full Text] [Related]
26. Current progress in the understanding of IgE-FcepsilonRI interaction.
Vangelista L
Int Arch Allergy Immunol; 2003 Aug; 131(4):222-33. PubMed ID: 12915765
[TBL] [Abstract][Full Text] [Related]
27. Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcγRIIb with Fc-engineered antibody.
Chu SY; Horton HM; Pong E; Leung IW; Chen H; Nguyen DH; Bautista C; Muchhal US; Bernett MJ; Moore GL; Szymkowski DE; Desjarlais JR
J Allergy Clin Immunol; 2012 Apr; 129(4):1102-15. PubMed ID: 22257644
[TBL] [Abstract][Full Text] [Related]
28. Improved FcγRIIb targeting functionally translates into enhanced inhibition of basophil activation.
Buschor P; Eggel A; Zellweger F; Stadler BM; Vogel M
Int Arch Allergy Immunol; 2014; 163(3):206-14. PubMed ID: 24557487
[TBL] [Abstract][Full Text] [Related]
29. Attenuation of IgE affinity for FcepsilonRI radically reduces the allergic response in vitro and in vivo.
Hunt J; Bracher MG; Shi J; Fleury S; Dombrowicz D; Gould HJ; Sutton BJ; Beavil AJ
J Biol Chem; 2008 Oct; 283(44):29882-7. PubMed ID: 18703499
[TBL] [Abstract][Full Text] [Related]
30. Antibody to FcεRIα Suppresses Immunoglobulin E Binding to High-Affinity Receptor I in Allergic Inflammation.
Hong JY; Bae JH; Lee KE; Kim M; Kim MH; Kang HJ; Park EH; Yoo KS; Jeong SK; Kim KW; Kim KE; Sohn MH
Yonsei Med J; 2016 Nov; 57(6):1412-9. PubMed ID: 27593869
[TBL] [Abstract][Full Text] [Related]
31. Monoclonal antibodies and synthetic peptides define the active site of FcepsilonRI and a potential receptor antagonist.
Rigby LJ; Trist H; Snider J; Hulett MD; Hogarth PM; Rigby LJ; Epa VC
Allergy; 2000 Jul; 55(7):609-19. PubMed ID: 10921459
[TBL] [Abstract][Full Text] [Related]
32. Structure of the human IgE-Fc C epsilon 3-C epsilon 4 reveals conformational flexibility in the antibody effector domains.
Wurzburg BA; Garman SC; Jardetzky TS
Immunity; 2000 Sep; 13(3):375-85. PubMed ID: 11021535
[TBL] [Abstract][Full Text] [Related]
33. Conformation of the isolated cepsilon3 domain of IgE and its complex with the high-affinity receptor, FcepsilonRI.
Henry AJ; McDonnell JM; Ghirlando R; Sutton BJ; Gould HJ
Biochemistry; 2000 Jun; 39(25):7406-13. PubMed ID: 10858288
[TBL] [Abstract][Full Text] [Related]
34. The intrinsic flexibility of IgE and its role in binding FcepsilonRI.
Harwood NE; McDonnell JM
Biomed Pharmacother; 2007 Jan; 61(1):61-7. PubMed ID: 17188833
[TBL] [Abstract][Full Text] [Related]
35. Structure of the Fc fragment of human IgE bound to its high-affinity receptor Fc epsilonRI alpha.
Garman SC; Wurzburg BA; Tarchevskaya SS; Kinet JP; Jardetzky TS
Nature; 2000 Jul; 406(6793):259-66. PubMed ID: 10917520
[TBL] [Abstract][Full Text] [Related]
36. Drastic up-regulation of Fcepsilonri on mast cells is induced by IgE binding through stabilization and accumulation of Fcepsilonri on the cell surface.
Kubo S; Matsuoka K; Taya C; Kitamura F; Takai T; Yonekawa H; Karasuyama H
J Immunol; 2001 Sep; 167(6):3427-34. PubMed ID: 11544335
[TBL] [Abstract][Full Text] [Related]
37. Engineering the Fab fragment of the anti-IgE omalizumab to prevent Fab crystallization and permit IgE-Fc complex crystallization.
Mitropoulou AN; Ceska T; Heads JT; Beavil AJ; Henry AJ; McDonnell JM; Sutton BJ; Davies AM
Acta Crystallogr F Struct Biol Commun; 2020 Mar; 76(Pt 3):116-129. PubMed ID: 32133997
[TBL] [Abstract][Full Text] [Related]
38. Thermal sensitivity and flexibility of the Cε3 domains in immunoglobulin E.
Doré KA; Davies AM; Drinkwater N; Beavil AJ; McDonnell JM; Sutton BJ
Biochim Biophys Acta Proteins Proteom; 2017 Nov; 1865(11 Pt A):1336-1347. PubMed ID: 28844738
[TBL] [Abstract][Full Text] [Related]
39. IL-3 but not monomeric IgE regulates FcεRI levels and cell survival in primary human basophils.
Zellweger F; Buschor P; Hobi G; Brigger D; Dahinden CA; Villiger PM; Eggel A
Cell Death Dis; 2018 May; 9(5):510. PubMed ID: 29724998
[TBL] [Abstract][Full Text] [Related]
40. Utilizing Fcepsilon-Bak chimeric protein for studying IgE-FcepsilonRI interactions.
Belostotsky R; Lorberboum-Galski H
Clin Immunol; 2004 Jan; 110(1):89-99. PubMed ID: 14962800
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
